Belite Bio Overview
Valuation check: BLTE's ROE is -11.34%, below the sector sector average of -5.93%.
Get informed when a big investor buys or sells
+ Follow-11.34%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Belite Bio (BLTE) currently reports a ROE of -11.34%. That is below the sector sector average of -5.93%. Use the charts on this page to explore Belite Bio's ROE history and peer comparisons.
Belite Bio's ROE of -11.34% is lower than the its sector sector average of -5.93%. That is roughly 91.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Belite Bio's current -11.34% should be judged against industry norms (sector average: -5.93%) and against BLTE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -11.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.93%. From there, open related valuation or income-statement pages for Belite Bio, and consider following BLTE for alerts when major investors trade the stock.
